KIDFamMap: A database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms

Nucleic Acids Research

Volumn 41, Issue D1, 2013, Pages

  Chiu, Yi Yuan ^a   Lin, Chih Ta ^a   Huang, Jhang Wei ^a   Hsu, Kai Cheng ^a   Tseng, Jen Hu ^a   You, Syuan Ren ^a   Yang, Jinn Moon ^a  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN ABL1; PROTEIN KINASE; PROTEIN TYROSINE KINASE; STAUROSPORINE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BINDING KINETICS; BINDING SITE; COMPUTER INTERFACE; COMPUTER PROGRAM; DRUG DATABASE; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; GENETIC CONSERVATION; HUMAN; KIDFAMMAP DATABASE; PRIORITY JOURNAL; PROTEIN FUNCTION; SEQUENCE HOMOLOGY;

CYCLIN-DEPENDENT KINASE 2; DATABASES, CHEMICAL; DISEASE; HUMANS; INTERNET; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; STAUROSPORINE;

EID: 84876517808     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gks1218     Document Type: Article

References (55)

1. Blume-Jensen, P. and Hunter, T. (2001) Oncogenic kinase signalling. Nature, 411, 355-365.
2. Cohen, P. (2002) Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov., 1, 309-315.
3. Noble, M.E.M., Endicott, J.A. and Johnson, L.N. (2004) Protein kinase inhibitors: insights into drug design from structure. Science, 303, 1800-1805.
4. Weinmann, H. and Metternich, R. (2005) Drug discovery process for kinase inhibitors. Chembiochem, 6, 455-459.
5. Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant, P., Atteridge, C.E., Campbell, B.T., Chan, K.W., Ciceri, P., Davis, M.I., Edeen, P.T. et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol., 26, 127-132.
6. Anastassiadis, T., Deacon, S.W., Devarajan, K., Ma, H.C. and Peterson, J.R. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol., 29, 1039-1045.
7. Davis, M.I., Hunt, J.P., Herrgard, S., Ciceri, P., Wodicka, L.M., Pallares, G., Hocker, M., Treiber, D.K. and Zarrinkar, P.P. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol., 29, 1046-1051.
8. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science, 298, 1912-1934.
9. Rose, P.W., Beran, B., Bi, C.X., Bluhm, W.F., Dimitropoulos, D., Goodsell, D.S., Prlic, A., Quesada, M., Quinn, G.B., Westbrook, J.D. et al. (2011) The RCSB Protein Data Bank: redesigned web site and web services. Nucleic Acids Res., 39, D392-D401.
10. Liu, T.Q., Lin, Y.M., Wen, X., Jorissen, R.N. and Gilson, M.K. (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res., 35, D198-D201.
11. Gaulton, A., Bellis, L.J., Bento, A.P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B. et al. (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res., 40, D1100-D1107.
12. Traxler, P. and Furet, P. (1999) Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther., 82, 195-206.
13. Liu, Y. and Gray, N.S. (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol., 2, 358-364.
14. McGregor, M.J. (2007) A pharmacophore map of small molecule protein kinase inhibitors. J. Chem. Info. Model., 47, 2374-2382.
15. Liao, J.J.L. (2007) Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem., 50, 409-424.
16. Chen, Y.F., Hsu, K.C, Lin, S.R., Wang, W.C, Huang, Y.C. and Yang, J.M. (2010) SiMMap: a web server for inferring site-moiety map to recognize interaction preferences between protein pockets and compound moieties. Nucleic Acids Res., 38, W424-W430.
17. Hsu, K.C, Cheng, W.C, Chen, Y.F., Wang, H.J., Li, L.T., Wang, W.C. and Yang, J.M. (2012) Core site-moiety maps reveal inhibitors and binding mechanisms of orthologous proteins by screening compound libraries. PLoS One, 7, e32142.
18. Hunter, S., Apweiler, R., Attwood, T.K., Bairoch, A., Bateman, A., Binns, D., Bork, P., Das, U., Daugherty, L., Duquenne, L. et al. (2009) InterPro: the integrative protein signature database. Nucleic Acids Res., 37, D211-D215.
19. Punta, M., Coggill, P.C, Eberhardt, RY., Mistry, J., Tate, J., Boursnell, C, Pang, N., Forslund, K., Ceric, G, Clements, J. et al. (2012) The Pfam protein families database. Nucleic Acids Res., 40, D290-D301.
20. Andreeva, A., Howorth, D., Brenner, S.E., Hubbard, T.J.P., Chothia, C. and Murzin, A.G (2004) SCOP database in 2004: refinements integrate structure and sequence family data. Nucleic Acids Res., 32, D226-D229.
21. Chen, CC, Lin, CY., Lo, Y.S. and Yang, J.M. (2009) PPISearch: a web server for searching homologous protein-protein interactions across multiple species. Nucleic Acids Res., 37, W369-W375.
22. Pargellis, C, Tong, L., Churchill, L., Cirillo, P.F., Gilmore, T., Graham, A.G, Grob, P.M., Hickey, E.R., Moss, N., Pav, S. et al. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol., 9, 268-272.
23. Dar, A.C. and Shokat, K.M. (2011) The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu. Rev. Biochem., 80, 769-795.
24. Norman, RA., Toader, D. and Ferguson, A.D. (2012) Structural approaches to obtain kinase selectivity. Trends Pharmacol. Sci., 33, 273-278.
25. Wang, Y.L., Xiao, J.W., Suzek, T.O., Zhang, J., Wang, JY., Zhou, Z.G, Han, LY., Karapetyan, K., Dracheva, S., Shoemaker, B.A. et al. (2012) PubChem's BioAssay database. Nucleic Acids Res., 40, D400-D412.
26. Magrane, M. and Consortium, U. (2011) UniProt Knowledgebase: a hub of integrated protein data. Database, 2011, bar009.
27. Kanehisa, M., Goto, S., Sato, Y., Furumichi, M. and Tanabe, M. (2012) KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res., 40, D109-D114.
28. Amberger, J., Bocchini, CA., Scott, A.F. and Hamosh, A. (2009) McKusick's Online Mendelian Inheritance in Man (OMIM®). Nucleic Acids Res., 37, D793-D796.
29. Chen, CC, Hwang, J.K. and Yang, J.M. (2006) (PS)(2): protein structure prediction server. Nucleic Acids Res., 34, W152-W157.
30. Chen, CC, Hwang, J.K. and Yang, J.M. (2009) (PS)(2)-v2: template-based protein structure prediction server. BMC Bioinform., 10, 366.
31. Altschul, S.F., Madden, T.L., Schaffer, AA., Zhang, J.H., Zhang, Z., Miller, W. and Lipman, D.J. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res., 25, 3389-3402.
32. Carhart, R.E., Smith, D.H. and Venkataraghavan, R. (1985) Atom pairs as molecular-features in structure activity studies - definition and applications. J. Chem. Info. Comput. Sci., 25, 64-73.
33. Willett, P., Barnard, J.M. and Downs, G.M. (1998) Chemical similarity searching. J. Chem. Info. Comput. Sci., 38, 983-996.
34. Haider, N. (2010) Functionality pattern matching as an efficient complementary structure/reaction search tool: an open-source approach. Molecules, 15, 5079-5092.
35. Yang, J.M. and Chen, C.C. (2004) GEMDOCK: a generic evolutionary method for molecular docking. Proteins, 55, 288-304.
36. Jones, G., Willett, P., Glen, R.C., Leach, A.R. and Taylor, R. (1997) Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol., 267, 727-748.
37. Kramer, B., Rarey, M. and Lengauer, T. (1999) Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins, 37, 228-241.
38. Ewing, T.J.A., Makino, S., Skillman, A.G. and Kuntz, I.D. (2001) DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput. Aided Mol. Des., 15, 411-428.
39. Shindyalov, I.N. and Bourne, P.E. (1998) Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Eng., 11, 739-747.
40. Hubbard, S.R. (1997) Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J, 16, 5572-5581.
41. Guex, N. and Peitsch, M.C. (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis, 18, 2714-2723.
42. Huse, M. and Kuriyan, J. (2002) The conformational plasticity of protein kinases. Cell, 109, 275-282.
43. Zhang, J.M., Yang, P.L. and Gray, N.S. (2009) Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer, 9, 28-39.
44. Fischmann, T.O., Smith, C.K., Mayhood, T.W., Myers, J.E., Reichert, P., Mannarino, A., Carr, D., Zhu, H., Wong, J., Yang, R.S. et al. (2009) Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry, 48, 2661-2674.
45. Herraez, A. (2006) Biomolecules in the computer - Jmol to the rescue. Biochem. Mol. Biol. Educ., 34, 255-261.
46. Chissoe, S.L., Bodenteich, A., Wang, Y.F., Wang, Y.P., Burian, D., Clifton, S.W., Crabtree, J., Freeman, A., Iyer, K., Li, J.A. et al. (1995) Sequence and analysis of the human Abl gene, the Bcr gene, and regions involved in the philadelphia chromosomal translocation. Genomics, 27, 67-82.
47. Faderl, S., Talpaz, M., Estrov, Z. and Kantarjian, H.M. (1999) Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med., 131, 207-219.
48. Radich, J.P. (2012) Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia. Cancer, 118, 300-311.
49. Cortes, J.E., Jones, D., O'Brien, S., Jabbour, E., Konopleva, M., Ferrajoli, A., Kadia, T., Borthakur, G., Stigliano, D., Shan, J.Q. et al. (2010) Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J. Clin. Oncol., 28, 392-397.
50. Weisberg, E., Choi, H.G., Ray, A., Barrett, R., Zhang, J.M., Sim, T., Zhou, W.J., Seeliger, M., Cameron, M., Azam, M. et al. (2010) Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR alpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood, 115, 4206-4216.
51. Huang, W.S., Metcalf, C.A., Sundaramoorthi, R., Wang, Y.H., Zou, D., Thomas, R.M., Zhu, X.T., Cai, L.S., Wen, D., Liu, S.Y. et al. (2010) Discovery of 3-[2-(Imidazo[1, 2-b]pyridazin-3-yl) ethynyl]-4-methyl-N-{4-[(4- methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I Gatekeeper Mutant. J. Med. Chem., 53, 4701-4719.
52. Brose, M.S., Volpe, P., Feldman, M., Kumar, M., Rishi, I., Gerrero, R., Einhorn, E., Herlyn, M., Minna, J., Nicholson, A. et al. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res., 62, 6997-7000.
53. Ackerley, S., Grierson, A.J., Banner, S., Perkinton, M.S., Brownlees, J., Byers, H.L., Ward, M., Thornhill, P., Hussain, K., Waby, J.S. et al. (2004) p38 alpha stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Mol. Cell. Neurosci., 26, 354-364.
54. Reichardt, P., Blay, J.Y., Gelderblom, H., Schlemmer, M., Demetri, G.D., Bui-Nguyen, B., McArthur, G.A., Yazji, S., Hsu, Y., Galetic, I. et al. (2012) Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann. Oncol., 23, 1680-1687.
55. Richardson, C.J., Gao, Q., Mitsopoulous, C., Zvelebil, M., Pearl, L.H. and Pearl, F.M.G. (2009) MoKCa database - mutations of kinases in cancer. Nucleic Acids Res., 37, D824-D831.